🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHad a FibroScan and do not understand my results - help Page 2

Had a FibroScan and do not understand my results - help

tampaLisa73 Tue, May 12, 2026 at 1:51 AM 10 replies 450 viewsPage 2 of 2
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
May 12, 2026 at 10:10 AM#6
Dr.CardioMD said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase 3 ATTAIN trial. NASH resolution was achieved in ~60% of patients[1].

This is relevant to liver and MASH because survodutide's glucagon agonism specifically targets hepatic lipid metabolism — making it potentially the best-in-class agent for NASH/MAFLD comorbid with obesity.

References:
[1] Sanyal AJ, et al. N Engl J Med. 2024.
Last edited: May 12, 2026 at 3:10 PM
1 21paul_denver
Reply Quote Save Share Report
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
May 12, 2026 at 1:27 PM#7
tampaLisa73 said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

50 20DoseLogDan, SleepFixSam, PurityPaulOR and 47 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
May 12, 2026 at 4:44 PM#8
PharmD_Rodriguez said:
ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…

Coming at PharmD_Rodriguez’s question from a different direction. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

49 19tane_welly, Dr.PathRoch, mona_PHX and 46 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
mel_PDX
Member
189
890
Dec 2024
Portland, OR
May 12, 2026 at 8:01 PM#9

Following on from rick_sfbay — and this may be the naive question:

What would you measure differently if you were starting again?

48 18BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 45 others
Reply Quote Save Share Report
tampaLisa73
Member
312
1,456
Oct 2024
Tampa, FL
May 13, 2026 at 11:46 AM#10

OP back with an update, since a thread like this is useless without one.

For the archive: it took about six weeks rather than the two I expected, and the difference between those two numbers was the whole of my problem.

14 12TomFromTexas, mike.trainer_LA, sarah_nash92 and 11 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register